Copertina

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Nobuharu Tamaki, Takefumi Kimura, Shun‐Ichi Wakabayashi, Takeji Umemura, Masayuki Kurosaki, Rohit Loomba, Namiki Izumi
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: M et ALD and Risk of Gastrointestinal Cancer—What Can We Learn From Japan? Authors' Reply
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
di: Nobuharu Tamaki, et al.
Pubblicazione: (2025)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
di: Nabil Noureddin, et al.
Pubblicazione: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
di: Shun‐Ichi Wakabayashi, et al.
Pubblicazione: (2026)

Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
di: Nobuharu Tamaki, et al.
Pubblicazione: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
di: Samer Gawrieh, et al.
Pubblicazione: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
di: Carolin V. Schneider, et al.
Pubblicazione: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
di: Donghee Kim, et al.
Pubblicazione: (2024)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
di: Takefumi Kimura
Pubblicazione: (2025)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
di: Richie Manikat, et al.
Pubblicazione: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world
di: Abdel‐Aziz Shaheen, et al.
Pubblicazione: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
di: Parminder Kaur, et al.
Pubblicazione: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
di: Yewan Park, et al.
Pubblicazione: (2024)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
di: Maral Amangurbanova, et al.
Pubblicazione: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
di: Federica Tavaglione, et al.
Pubblicazione: (2025)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
di: Manya Prasad, et al.
Pubblicazione: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
di: María Hernández‐Pérez, et al.
Pubblicazione: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
di: Richie Manikat, et al.
Pubblicazione: (2024)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

A Message From the Editors
di: Colin W. Howden, et al.
Pubblicazione: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
di: Mohamed I. Elsaid, et al.
Pubblicazione: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
di: Mohamad Jamalinia, et al.
Pubblicazione: (2024)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
di: Antonio De Vincentis, et al.
Pubblicazione: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
di: Rocio Enriquez, et al.
Pubblicazione: (2024)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
di: Selena Z. Kuo, et al.
Pubblicazione: (2025)

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study
di: Angelo Armandi, et al.
Pubblicazione: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
di: Xianhua Mao, et al.
Pubblicazione: (2024)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
di: Nipun Verma, et al.
Pubblicazione: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
di: Sung Won Chung, et al.
Pubblicazione: (2024)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
di: Maryam Zafer, et al.
Pubblicazione: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
di: Luis Antonio Díaz, et al.
Pubblicazione: (2025)

Insulin‐like growth factor‐1 in cirrhosis is linked to hepatic dysfunction and fibrogenesis and predicts liver‐related mortality
di: Lukas Hartl, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019
di: Pojsakorn Danpanichkul, et al.
Pubblicazione: (2024)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
di: Donghee Kim, et al.
Pubblicazione: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
di: Donghee Kim, et al.
Pubblicazione: (2025)

Identification of four novel acute‐on‐chronic liver failure clusters with distinct clinical trajectories and mortality using machine learning methods
di: Nipun Verma, et al.
Pubblicazione: (2024)